Business
CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL
CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL.
About this update from Canaquest Medical Corporation
[{"type":"text","content":"\n TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the \"Company\" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has been approved to raise capital on The OCMX™, an online portal that publicizes and provides financial connections to public and privately held investment opportunities. Planned use of proceeds for CanaQuest’s raise include helping further facilitate a funding pathway for FDA drug approval, which is already underway. The OCMX™ has spent considerable time completing its due diligence on the Company and concluded that there is indeed a tremendous opportunity for Investors and Advisors. The OCMX™ noted that, “CanaQuest Medical Corporation exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.” OCMXListing - https://theocmx.com/marketplace/canaquest/ INVESTMENT OPPORTUNITY HIGHLIGHTS 1) Based on the preclinical trial results, the Company believes that Mentanine® has several advantages compared to other CBD products. For example, the Mentanine® formula, manufacturing process and drug delivery significantly increases the efficacy of the CBD, thus requiring a lower amount of CBD for medication purposes, eliminating negative side effects associated with high CBD consumption. 2) The synergistic effect of the formula, which allows the drug to cross the Blood Brain Barrier, will provide the opportunity for Mentanine® to treat numerous mental health issues. It can also be used as a direct alternative to THC products. 3)In June 2018, Epidiolex was approved by the US FDA as the only CBD product approved by the FDA. As a result, GW Pharma generated in excess of $290 Million in revenue.4) Under the Pharmaceutical regulatory pathway (pursued by GW Pharma), CanaQuest is focusing on obtaining approval for two scientifically developed products to deal with mental health while eliminating significant negative sides effects as compared to other CBD and THC products on the market today. Mentanine®Rx - CBD based formulation, and Mentabinol® Rx – THC based fo...